Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct 31;14(5):2290-2292.
doi: 10.21037/jgo-2023-04. Epub 2023 Sep 22.

Determinants of gemcitabine response in pancreatic cancer: are we there?

Orla M Fitzpatrick  1 , Grainne M O'Kane  1   2
Affiliations
Editorial

Determinants of gemcitabine response in pancreatic cancer: are we there?

Orla M Fitzpatrick et al. J Gastrointest Oncol. .
No abstract available

Keywords: Pancreatic cancer; RNA; biomarker; gemcitabine.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-2023-04/coif). GMO has received Honoraria/Consulting fees from AstraZeneca, Roche, Servier, MSD, Incyte and Eisai. She has received grant funding from Roche. OMF has no conflicts of interest to report.

Comment on

  • Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.
    Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, Bertaut A, Pierrat F, Evesque L, Gamez A, Cros J, Rederstorff E, Petit E, Adnet J, Saint A, Drouillard A, Kempf E, Soularue E, Vincent J, Baumgaertner I, Hennequin A, Tournigand C, Lopez Trabada Ataz D, Bengrine L, Lepage C, Manfredi S, Afchain P, Trouilloud I, Gagnaire A, LoConte NK, Bachet JB. Piquemal D, et al. J Gastrointest Oncol. 2023 Apr 29;14(2):997-1007. doi: 10.21037/jgo-22-946. Epub 2023 Apr 10. J Gastrointest Oncol. 2023. PMID: 37201091 Free PMC article.

References

    1. O’Kane GM, Ladak F, Gallinger S. Advances in the management of pancreatic ductal adenocarcinoma. CMAJ 2021;193:E844-51. 10.1503/cmaj.201450 - DOI - PMC - PubMed
    1. Wainberg ZA, Melisi D, Macarulla T, et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol 2023;41:LBA661. 10.1200/JCO.2023.41.4_suppl.LBA661 - DOI - PMC - PubMed
    1. Reiss KA, Mick R, O’Hara MH, et al. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 2021;39:2497-505. 10.1200/JCO.21.00003 - DOI - PubMed
    1. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 2019;381:317-27. 10.1056/NEJMoa1903387 - DOI - PMC - PubMed
    1. Ramanathan RK, McDonough SL, Philip PA, et al. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. J Clin Oncol 2019;37:1062-9. 10.1200/JCO.18.01295 - DOI - PMC - PubMed